Skip to main content

Table 2 Correlations between changes in GLP-1, NO, CIMT and other laboratory data following acarbose treatment

From: Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary report

  Δfasting GLP-1 Δ2 h postprandial GLP-1 ΔNO ΔNOS
  R value P value R value P value R value P value R value P value
Weight -0.143 0.506 0.014 0.950 0.024 0.911 0.121 0.574
BMI -0.128 0.550 0.027 0.899 0.038 0.861 0.138 0.519
GHbA1c -0.491 0.015 -0.636 0.001 -0.143 0.504 -0.149 0.488
FPG -0.185 0.388 -0.481 0.017 0.038 0.859 -0.108 0.617
P2PG -0.181 0.398 -0.110 0.608 0.241 0.256 0.007 0.973
ln Insulin (0 h) -0.176 0.411 0.145 0.498 0.285 0.177 0.363 0.081
ln Insulin (2 h) -0.035 0.871 0.084 0.696 0.135 0.528 0.079 0.713
mean CIMT(mm) -0.384 0.064 -0.628 0.001 -0.577 0.003 -0.314 0.135
NO 0.245 0.249 0.452 0.026 - - 0.449 0.028
NOS 0.268 0.205 0.561 0.004 0.449 0.028 - -
  1. Δ: The change of values following acarbose treatment; ln: natural logarithm -transformed values; BMI: body mass index; HbA1c: glycated haemoglobin A1c; FPG: fasting plasma glucose; P2PG: 2 hour postprandial plasma glucose; CIMT: carotid intima-media thickness; NO: nitric oxide; NOS: nitric oxide synthase.